Kornitzer Capital Management Inc. KS Purchases 1,031 Shares of AstraZeneca PLC (NASDAQ:AZN)

Kornitzer Capital Management Inc. KS boosted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 0.3% in the third quarter, Holdings Channel.com reports. The fund owned 360,312 shares of the company’s stock after acquiring an additional 1,031 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in AstraZeneca were worth $28,072,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in AZN. Martin Investment Management LLC lifted its position in AstraZeneca by 2.8% during the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after acquiring an additional 7,615 shares during the last quarter. Integrated Advisors Network LLC raised its stake in AstraZeneca by 46.6% in the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after buying an additional 13,860 shares during the last quarter. Creative Planning boosted its holdings in AstraZeneca by 8.0% in the third quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after acquiring an additional 16,692 shares in the last quarter. TD Asset Management Inc grew its stake in shares of AstraZeneca by 8.6% during the first quarter. TD Asset Management Inc now owns 1,537,410 shares of the company’s stock worth $104,160,000 after acquiring an additional 121,876 shares during the last quarter. Finally, Northcape Wealth Management LLC purchased a new position in shares of AstraZeneca in the 2nd quarter valued at approximately $269,000. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Trading Down 0.1 %

NASDAQ:AZN traded down $0.04 on Thursday, reaching $63.81. The company’s stock had a trading volume of 3,210,361 shares, compared to its average volume of 5,117,211. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The stock has a 50 day moving average price of $78.45 and a 200 day moving average price of $78.75. The firm has a market cap of $197.85 billion, a price-to-earnings ratio of 30.85, a price-to-earnings-growth ratio of 1.32 and a beta of 0.47. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, TD Cowen boosted their price target on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.